Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients

Vox Sanguinis
B C McLeodR J Sassetti

Abstract

Platelet transfusions from RhD-positive (D-positive) donors are often given to RhD-negative (D-negative) cancer patients. The low observed rate of alloimmunization has been attributed to disease and therapy-related immunosuppression. We have studied the occurrence of alloimmunization in 16 D-negative patients who did not have detectable anti-D prior to autologous bone marrow transplantation for malignant disease. All received D-positive platelets, but no other D-positive blood product. Three patients (19%) developed anti-D at 13, 24 and 83 days, respectively, after first receiving D-positive platelets, and after a total dose of 53, 65 and 119 D-positive platelet unit equivalents, respectively. Two of them also developed anti-C. The 13 patients in whom anti-D was not detected were also heavily transfused with D-positive platelets (mean +/- SD = 136 +/- 82 platelet unit equivalents). In 6 of them, the last recorded antibody screen was less than 3 months after the first D-positive platelets, and may not exclude a primary immune response. Thus, despite profound immunosuppression associated with autologous marrow transplantation, alloimmune responses to D-positive red cells in platelet concentrates can occur in some D-negative recip...Continue Reading

Citations

Jan 1, 2008·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Peter Hellstern
Dec 10, 2013·Bone Marrow Transplantation·G S BoothB N Savani
Apr 21, 2010·Best Practice & Research. Clinical Anaesthesiology·Bruce D Spiess
Aug 24, 2007·Transfusion·Mark H Yazer, Darrell J Triulzi
Oct 7, 2014·British Journal of Haematology·Joan CidUNKNOWN Biomedical Excellence for Safer Transfusion collaborative
Nov 24, 2004·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·N ContentinH Tilly
Aug 21, 2002·Hematology·G GandiniG Aprili
Sep 20, 2005·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·P ChamouniP Czernichow
Oct 1, 2015·Asian Journal of Transfusion Science·Serena ValsamiMarianna Politou
Oct 6, 2014·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·H Chambost
Dec 30, 2014·Transfusion Medicine Reviews·Susan NahirniakUNKNOWN International Collaboration for Transfusion Medicine Guidelines
May 14, 2016·Transfusion Medicine·J N SeheultM H Yazer
Sep 8, 2011·Bone Marrow Transplantation·S D RowleyP Bhattacharyya
Jul 6, 2004·Bone Marrow Transplantation·R RaimondiUNKNOWN Gruppo Italiano Trapianto di Midolla Osseo
Sep 29, 2004·Pediatric Blood & Cancer·Edward C C WongNaomi L C Luban
Nov 29, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles A SchifferKenneth C Anderson
Sep 29, 2015·Current Opinion in Hematology·Joan CidMiguel Lozano
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A SchifferUNKNOWN American Society of Clinical Oncology
Jun 22, 2018·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Johanna ReckhausBehrouz Mansouri Taleghani
Jun 22, 2018·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Ana VillalbaPilar Solves
Jun 17, 2020·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·P Moncharmont

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.